VolitionRX Ltd VNRX:NYSE American

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 03/05/21 EST
3.79quote price arrow up+0.01 (+0.26%)
Volume
370,377
52 week range
2.22 - 6.67

...

Loading . . .

KEY STATS

  • Open3.82
  • Day High3.86
  • Day Low3.53
  • Prev Close3.78
  • 52 Week High6.67
  • 52 Week High Date02/09/21
  • 52 Week Low2.22
  • 52 Week Low Date03/18/20
  • Market Cap196.59M
  • Shares Out51.87M
  • 10 Day Average Volume0.44M
  • Dividend-
  • Dividend Yield-
  • Beta1.91
  • 1 Year % Change3.84

RATIOS/PROFITABILITY

  • EPS (TTM)-0.44
  • P/E (TTM)-8.68
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-18.385M
  • ROE (MRQ)-102.06%
  • Revenue (MRQ)10,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-297,871.50%
  • Debt To Equity (MRQ)18.75%

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest VolitionRX Ltd News

There is no recent news for this security.

Latest VNRX News From Our Partners

February 10, 2021

QUOTE FINDER

Profile

MORE
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology...
Martin Faulkes
Chairman
Cameron Reynolds
Chief Executive Officer
Gaetan Michel
Chief Operating Officer
Terig Hughes
Chief Financial Officer
Mark Eccleston
Chief Technology Officer
Address
Galleria Oaks B
Austin, TX
78738-6439
United States